Remdesivir for COVID-19 Pneumonia Patients

Remdesivir was administered intravenously in: a. patients hospitalized for pneumonia due to COVID-19, needing non-invasive ventilation; b. patients having some comorbidities (e.g., type 2 diabetes, cancer) that can increase the risk of severe COVID-19 forms. These indications follow the national guidelines available at the time of inclusion^{2 (link)}. According to local protocol, all the patients received 200 mg of Remdesivir on the first day, followed by 100 mg once daily for the subsequent 9 days, 4 days, or 2 days as a maintenance dose, for a total of 10, 5, or 3 days of treatment. All the patients received the first dose of Remdesivir within the first three days of disease. Since patients having severe renal (creatinine clearance < 30 ml/min) or hepatic failure (ALT > 5x) cannot take Remdesivir, they were excluded from the analyses. Finally, we also recorded potential side effects due to this medication.

Free full text: Click here

Veronese N., Di Gennaro F., Frallonardo L., Ciriminna S., Papagni R., Carruba L., Agnello D., De Iaco G., De Gennaro N., Di Franco G., Naro L., Brindicci G., Rizzo A., Bavaro D.F., Garlisi M.C., Santoro C.R., Signorile F., Balena F., Mansueto P., Milano E., Giannitrapani L., Fiordelisi D., Mariani M.F., Procopio A., Lattanzio R., Licata A., Vernuccio L., Amodeo S., Guido G., Segala F.V., Barbagallo M, & Saracino A. (2024). Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis. Scientific Reports, 14, 9303.

Publication 2024

Corresponding Organization :

Other organizations : University of Palermo, University of Bari Aldo Moro

Top 5 similar protocols

Variable analysis

independent variables

Dose of Remdesivir (200 mg on first day, followed by 100 mg once daily for 10, 5, or 3 days)

dependent variables

Pneumonia due to COVID-19 requiring non-invasive ventilation
Presence of comorbidities (e.g., type 2 diabetes, cancer) that can increase the risk of severe COVID-19 forms
Potential side effects due to Remdesivir medication

control variables

All patients received the first dose of Remdesivir within the first three days of disease
Patients with severe renal (creatinine clearance < 30 ml/min) or hepatic failure (ALT > 5x) were excluded

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!